Emambux Sheik, Kind Michele, Le Loarer Francois, Toulmonde Maud, Stoeckle Eberhard, Italiano Antoine
Departments of aMedical Oncology bRadiology cPathology dSurgery, Institut Bergonie, Bordeaux, France.
Anticancer Drugs. 2017 Oct;28(9):1053-1055. doi: 10.1097/CAD.0000000000000536.
Desmoplastic small round-cell tumor is a rare but highly aggressive tumor occurring mainly in adolescents and young adults. Prolonged progression-free survival has been documented in patients who have undergone aggressive multimodality therapy - that is, multiagent intensive chemotherapy, debulking surgery, and radiation therapy. Eribulin is a microtubule-dynamics inhibitor, and it has recently been shown to be active in liposarcomas. In preclinical models, eribulin activities have also been shown to occur in Ewing's sarcoma cell lines, rhabdomyosarcomas and osteosarcomas. In this study, we report three cases of male patients suffering from desmoplastic small round-cell tumor and the clinical response to eribulin in two of them.
促纤维增生性小圆细胞瘤是一种罕见但具有高度侵袭性的肿瘤，主要发生于青少年和年轻成年人。接受积极多模式治疗（即多药强化化疗、减瘤手术和放射治疗）的患者已被证明有较长的无进展生存期。艾瑞布林是一种微管动力学抑制剂，最近已显示其在脂肪肉瘤中具有活性。在临床前模型中，艾瑞布林在尤因肉瘤细胞系、横纹肌肉瘤和骨肉瘤中也表现出活性。在本研究中，我们报告了3例促纤维增生性小圆细胞瘤男性患者，其中2例对艾瑞布林的临床反应。
